54 results about "T reg cells" patented technology

The invention discloses a sorting and amplification method of human peripheral blood CD4+CD25+Foxp3+ regulatory T cells, and belongs to the field of cell sorting amplification. The sorting and amplification method of the human peripheral blood CD4+CD25+Foxp3+ regulatory T cells specifically comprises the following steps: (1) separating peripheral blood mononuclear cells; (2) performing MACS (magnetic activated cell sorting) on CD4+CD25+Foxp3+Treg cells; and (3) performing in-vitro culture and amplification on the CD4+CD25+Foxp3+Treg cells, and finally performing amplification and culture to obtain the human peripheral blood CD4+CD25+Foxp3+ regulatory T cells. According to the sorting and amplification method disclosed by the invention, human peripheral blood CD4+CD25+Treg cells are successfully separated by using an immuno-magnetic bead two-step process, and the purity of the human peripheral blood CD4+CD25+Treg cells is subjected to flow identification to ensure that the purity of the finally-obtained CD4+CD25+Treg cells can reach 97%, and the activity of the cells can reach more than 95%.

An affinity ligand is reactive to the GARP protein may be capable of binding to an extracellular domain of GARP protein expressed on regulatory T (Treg) cells. The affinity ligand may be an antibody and may be used to identify Treg cells. A method comprises providing a blood sample from a subject and determining the amount of Treg cells in that sample. A composition containing Treg cells may be administered to an individual to suppress effector T cell activity in the individual. A composition containing an affinity ligand capable of binding to a GARP domain may be administered to an individual to suppress Treg cell activity and increase effector T cell activity in the individual. A kit for detecting Treg cells may include an affinity ligand reactive with mammalian GARP protein.

The present invention provides nanoparticle-coupled tolerogenic Treg cell therapy for treatment of immune and / or autoimmune disorders. In certain specific embodiments, the present invention can be used in the prevention and / or treatment of autoimmune diseases including, but not limited to, type 1 diabetes, lupus erythematosus (SLE), multiple sclerosis (MS), inflammatory bowel disease (IBD), rheumatoid arthritis, oophoritis, and autoimmune pathology associated with Graft versus Host Disease (GvHD) following hematopoietic stem cell transplantation.

A method of identifying an antigen-specific regulatory T cell (Treg) from a subject is discussed wherein the method comprises quantitatively or qualitatively detecting co-expression of each of cell markers CD4, CD25 and CD134, or alternatively, N each of cell markers CD8, CD25 and CD137, as well as one or more cell markers selected from the group of Treg cell markers consisting of CD39, CD73, CD127, CTLA-4 and Foxp3 on a cell in a suitable lymphocyte-containing sample from the subject in response to exposure to a target antigen. Also discussed are methods of isolating and expanding the identified antigen-specific Treg population, which may permit antigen-specific Treg cell therapy.

The present invention provides methods and compositions for expanding Treg cells ex vivo or in vivo using one or more conjugates comprising a costimulatory moiety that stimulates at least one of three signals involved in Treg cell development and / or using dendritic cells pulsed with antigens and modified to display TGF-β, or hematopoetic stem cells or bone marrow cells modified to display TGF-β. The methods and compositions are useful, for example, in the treatment and prevention of autoimmune disease, including Type 1 diabetes and in preventing foreign graft rejection, as well as to establish mixed chimerism, induce tolerance to autoantigens, alloantigens or xenoantigens, beta cell regeneration, prevention of foreign graft rejection, and treatment of a genetically inherited hematopoietic disorder.

The invention discloses application of L-fucose in medicines and health-care products for treating gastrointestinal lesions. The L-fucose is used for treating the gastrointestinal lesions, such as inflammatory bowel disease, functional gastrointestinal disorder and irritable bowel syndrome. The medicine is a carbohydrate medicine, since the adverse effect is less, and the tolerance of a patient is good, so that the medicine can be widely applied into clinic. The medicine has the advantages that the L-fucose is used in an early period of the gastrointestinal lesions, the activation of mesenteric lymph node Treg cells is regulated by DC cells, the differentiation potential of colons Th1 and Th17 is inhibited, the generation of bile acid is inhibited by regulating the intestinal flora, the function of inhibiting the contraction and spasm of intestinal muscles is realized by an nNOS path, the intestinal inflammation and weight-losing conditions are improved, and the patient can obtain an obvious long-term prognosis benefit; because of limitations of related existing therapy medicines, namely multiple medicine types, large side effect and poor compliance, a new therapy strategy for treating the patients with the gastrointestinal lesions, such as the inflammatory bowel disease, the functional gastrointestinal disorder and the irritable bowel syndrome, is provided.

An object of the present invention is to provide a technique to distinguish between Treg cells and activated T cells in a live state. Another object of the present invention is to provide a pharmaceutical composition for immunostimulation that can reduce the number of Treg cells in vivo and effectively express the immune response of activated T cells. In the method of the present invention, Treg cells are detected from test cells containing (i) regulatory T cells and (ii) at least one type of cell selected from the group consisting of naive T cells and activated T cells, wherein expressions of folate receptor 4 on the surfaces of cells are measured and Treg cells are detected using the expressions as an indicator. The present invention uses anti-folate receptor 4 antibody or folate receptor 4-binding fragment as an active ingredient contained in a pharmaceutical composition for immunostimulation.

The present invention provides materials and methods related to culturing stable Treg cells or in vivo expansion of stable Treg cells, the cells made by the methods, treatments for various inflammatory / autoimmune pathologies and transplant / graft rejection, and related materials. Ex vivo induction and expansion of the stable Tregs is described, including use of inducing compositions, such as certain mAbs and other compounds, along with expansion medium comprising IL-2. In vivo expansion of stable Treg cells and treatments for various inflammatory / autoimmune pathologies and transplant / graft rejection are described, including the use of mAbs and their variants.

The invention relates to a culture solution of universal Treg cells and a culture method and application of the culture solution. The culture method of the culture solution of the universal Treg cellscomprises the following steps: S110, co-culturing CD4+ CD25+ Treg cells and hUC-MSCs according to a certain proportion for 48 h-72 h, and centrifuging to obtain supernatant; S220, preparing peripheral blood PBMC and plasma, inactivating the plasma, and centrifuging for later use; S330, adding cytokine, calcium ionophore, plasma obtained from S220 and a RPMI1640 culture solution into the supernatant obtained from S110 to prepare a Treg cell culture solution; S440, inoculating peripheral blood PBMC into the Treg cell culture solution prepared in S330 according to a certain density, and culturing for 48 h-96 h; S550, collecting cells, wherein the cell viability is greater than 90%, the cell expression of CD4+ CD25+ Foxp3+ Treg is greater than 65%, and CD4+ CD25+ Foxp3+ Helios+ Treg cells account for more than 90% of the cell expression of CD4+ CD25+ Foxp3+ Treg. The problems that Treg cell culture operation is complex and the period is too long are solved, and the problems that the content of CD4+ CD25+ Foxp3+ Helios+ Treg cells in peripheral blood is too low and Treg cell treatment cannot be implemented due to a patient with low quality of autologous Treg cells caused by the problemof diseases of the patient are solved.

The invention discloses a traditional Chinese medicine composition for regulating chronic hepatitis B. The traditional Chinese medicine composition comprises the following components in parts by weight: 10-20 parts of raw astragalus, 5-15 parts of radix sophorae flavescentis, 10-20 parts of fried Chinese yams, 5-15 parts of glossy privet fruits, 5-15 parts of semen cuscutae, 5-15 parts of rhizoma smilacis glabrae, 5-15 parts of radix curcumae, 10-20 parts of polygonum cuspidatum, 10-20 parts of underleaf pearls and 5-15 parts of salvia miltiorrhiza. The invention also provides application of the composition to preparation of a drug for treating chronic hepatitis B and regulating peripheral blood Treg cells. Concretely, the invention provides a decoction prepared according to the traditional Chinese medicine formula and application of the decoction to preparation of a drug for treating chronic hepatitis B by matching with a western drug. As a whole, the traditional Chinese medicine composition prepared according to the whole formula has the effects of tonifying the spleen and benefiting the kidneys as well as removing heat from the liver and dispersing blood stasis; and when being united with the western drug for treating chronic hepatitis B, the traditional Chinese medicine composition can be used for effectively regulating the peripheral blood Treg cells and is beneficial to the treatment of chronic hepatitis B.

An affinity ligand is reactive to the GARP protein may be capable of binding to an extracellular domain of GARP protein expressed on regulatory T (Treg) cells. The affinity ligand may be an antibody and may be used to identify Treg cells. A method comprises providing a blood sample from a subject and determining the amount of Treg cells in that sample. A composition containing Treg cells may be administered to an individual to suppress effector T cell activity in the individual. A composition containing an affinity ligand capable of binding to a GARP domain may be administered to an individual to suppress Treg cell activity and increase effector T cell activity in the individual. A kit for detecting Treg cells may include an affinity ligand reactive with mammalian GARP protein.

A method of identifying an antigen-specific regulatory T cell (Treg) from a subject is discussed wherein the method comprises quantitatively or qualitatively detecting co-expression of each of cell markers CD4, CD25 and CD134, or alternatively, each of cell markers CD8, CD25 and CD137, as well as one or more cell markers selected from the group of Treg cell markers consisting of CD39, CD73, CD127, CTLA-4 and Foxp3 on a cell in a suitable lymphocyte-containing sample from the subject in response to exposure to a target antigen. Also discussed are methods of isolating and expanding the identified antigen-specific Treg population, which may permit antigen-specific Treg cell therapy.

The invention belongs to the technical field of cell culture in vitro, and particularly relates to a preparation method of high-purity, high-multiplication capacity and high-cytotoxin activity CIK (cytokine induced kill) cell. The method comprises the following steps: collecting and separating peripheral blood mononuclear cell of a patient, eliminating CD4+CD25+Treg cell by means of Mini MACS (magnetic active cell sorting) method, and sorting to obtain CD3+, CD4+ and CD8+T cells; and putting the obtained cells into culture solution containing phytohemagglutinin (PHA), so that the PHA concentration in the suspension liquid is 100ng / ml, hatching for 24h under the culture condition of 5% CO2 at 37 DEG C, transferring the hatched suspension liquid into a cell culture bottle coated by CD3 monoclonal antibody (1mug / ml), adding IFN (interferon)-gamma (1000U / ml), adding IL (interleukin)-2(500U / ml) and IL (interleukin)-21(1000U / ml) after 48h, compensating sodium selenite-containing (0.005mg / L)cell culture after four days, and continuously culturing for 7-14 days to obtain the high-purity, high-multiplication capacity and high-cytotoxin activity CIK (cytokine induced kill) cell. The quantity, the activity and the purity of the CIK cell which is prepared by the method and amplified in vitro are improved, so that the antineoplastic function of the CIK is enhanced.